We live in the age of advanced science and smarter tools—and at Codetta Bio, they’re harnessing that progress to solve real-world challenges in diagnostics and research. Their vision is impactful in redefining how multi-omics data powers precision medicine.

Life-threatening diseases like cancer are far more treatable when caught early. That’s why Codetta Bio is committed to transforming how we detect and monitor disease—starting at the molecular level. Our multi-omic technology enables researchers to measure DNA, RNA, and protein targets simultaneously from the same sample, using just one streamlined platform.

Join us for an insightful conversation with Jacques Corriveau, CEO of Codetta Bio, as he shares what is new in the field of biotechnology, especially in diagnostic innovation.

1. What is the motivation behind the establishment of Codetta Bio™ and what is the mission of the company?

Codetta Bio was founded on a simple yet urgent observation. Despite dramatic advances in genomics, proteomics, and single-cell analysis, most labs still stitch together multiple instruments and workflows to answer a single multi-omic question. That fragmentation slows down discovery, increases costs, and often forces researchers to choose between depth and breadth of data.

Our team, which includes digital PCR experts, immunoassay veterans, and translational scientists, aims to remove this obstacle. The result is the Concerto™ System, the first platform that enables simultaneous quantification of DNA, RNA, and proteins from the same sample, on a single chip, with digital-level precision.

Codetta Bio’s mission is to make comprehensive, multi-omic biology as routine as a standard PCR run.

Our mission is to:

• Unify multi-omic analysis so labs can move from sample to insight without switching instruments
• Make advanced assays more accessible by reducing costs and simplifying workflows
• Accelerate breakthrough science in oncology, immunology, neuroscience, and precision medicine by providing researchers with the complete molecular picture in one experiment

In short, we are here to transform multi-omic complexity into a single, intuitive workflow so scientists can focus on discovery instead of workarounds.

2. How exactly is your company making a difference in the fields of research and diagnostic development?

Although the Concerto™ System is currently for research use only, it fills a critical gap between basic discovery and regulated diagnostic development. This is an area where many promising biomarkers often stall.

Impact on Research and Diagnostic Development:

Accelerated Biomarker Selection
Researchers can screen genomic and protein markers in a single experiment, quickly identifying the highest-value signatures for potential companion diagnostic assay insights.

Higher Confidence in Stratification
Concerto’s matched multi-omic data reduce the risk of false leads, enabling translational teams to stratify patients earlier and design more precise clinical studies.

Cost-Effective Bridge to IVD
Because the platform emulates digital PCR precision and qPCR dynamic range, assays can be ported to clinical-grade workflows with minimal reengineering. This approach saves both time and money.

Democratization of Complex Assays
Labs that could never afford multiple platforms can now access comprehensive biology on a single instrument, broadening participation in biomarker innovation.

3. What specific products or services does Codetta Bio™ offer, and how do they work?

4. Can you elaborate on the Codetta Bio™ Concerto System and its key features?

The Codetta Bio™ Concerto System is a purpose-built platform designed for laboratories that require complete molecular insight, including DNA, RNA, and protein, from the same precious sample in a single run.

Below are the key features that set the Concerto System apart:

4. Would you like to share some of the promising areas of research Codetta Bio™ is currently exploring?

While Codetta Bio’s Concerto™ platform is broadly applicable, several research areas are generating the most excitement and yielding the most compelling early data among our collaborators. These include oncology, immuno-oncology, neurodegenerative diseases, inflammatory diseases, vaccine development, and infectious diseases.

5. What innovative technologies or approaches is Codetta Bio™ using in its research and development efforts?

Codetta’s core innovation is a unified assay architecture that enables simultaneous detection of proteins and nucleic acids in the same sample, within the same lane, and during the same run.

Unlike traditional platforms that require separate workflows for genomics and proteomics, Codetta integrates both modalities, allowing researchers to resolve pathway-level biology in a single assay. The detection chemistry is optimized for high signal-to-noise ratios and sub-femtomolar sensitivity.

6. What is the ultimate goal of your business, and what kind of influence do you hope to have on the biotechnology industry?

Our goal is to turn every laboratory into a multi-omic powerhouse, ensuring that the next major breakthrough is not delayed by outdated technology.

By setting a new standard for speed, simplicity, and scalability in biomarker measurement, Codetta Bio aims to redefine what scientists expect from their instrumentation. Ultimately, we hope to help translate more discoveries into patient-stratified therapeutics and diagnostics around the world.

7. How does Codetta Bio™ measure the success of its research and development efforts, and what metrics do you use to evaluate progress?

We view research and development success as a balance between scientific rigor, product-market fit, and customer impact.

To keep this balance measurable, we track a tiered set of objectives and key results (OKRs) across the organization. By tying scientific performance to user adoption and financial outcomes, we ensure that every R&D sprint moves Codetta Bio closer to its goal of making routine, high-plex multi-omics accessible to every lab.

8. What are the most significant challenges facing Codetta Bio™ in its research and development efforts, and how do you plan to address them?

Pushing a first-in-class, multi-omic platform from concept to widespread adoption requires a combination of scientific excellence, engineering innovation, and trust-building.

By simultaneously addressing technical rigor, supply chain reliability, and translational readiness, Codetta Bio keeps its R&D engine focused on what matters most: making comprehensive multi-omics an everyday, dependable reality for the life sciences community.

9. How does Codetta Bio™ collaborate with other researchers, institutions, or industry partners to advance its research and development efforts?

Collaboration is embedded in Codetta Bio’s DNA. A platform designed to unify multi-omic data can only succeed if it also unifies the expertise of the scientific community.

We offer a range of partnership models that allow researchers, institutions, and industry partners to engage at a level that best aligns with their goals. Below are some recent examples:

• Early-access and pilot projects
• Co-development and validation with pharmaceutical translational teams
• Technology and ecosystem alliances for next-generation materials

10. Can you share with us some of your notable breakthrough achievements and accomplishments?

We have built a growing patent portfolio that covers our core assay chemistry, bead-based multiplexing system, and multi-analyte quantification technologies, ensuring we and our customers remain at the forefront of scientific advancement well into the future.

We have also been fortunate to receive strong support from both our internal team and the broader investor community. This backing has allowed us to establish robust operational and commercial readiness, along with a first-class customer and technical support program.
Most recently, we achieved ISO 9001:2015 certification, further validating the strength and reliability of our quality management systems.

11. Are there any exciting upcoming projects you would like to share with us?

Absolutely. We have several KOL-driven initiatives coming online that highlight where the Concerto™ platform is headed next. These collaborations place Concerto™ in the hands of world-class investigators who are tackling some of the most challenging translational questions. This demonstrates that high-plex, single-sample multi-omics is no longer just a wish list item — it is now a working reality.

12. Great results demand a smart and efficient team. Can you tell us about your team’s strength and how it contributes to the company’s success?

Codetta Bio’s greatest asset is a deliberately cross-disciplinary team that functions like a well-rehearsed orchestra, with each section performing at a high level while working in harmony. When a pharmaceutical partner requests a 20-plex nucleic acid and protein panel within eight weeks, our assay development, platform, and software teams collaborate closely, while our commercial team confidently commits to delivery timelines.

This level of coordination and efficiency allows Codetta Bio to consistently deliver breakthroughs on schedule and turn early adopters into long-term champions.

13. Jacques Corriveau, as CEO of Codetta Bio™, how do you envision leading your team to phenomenal success and leaving a lasting legacy in the field of biotechnology?

As the CEO of Codetta Bio™, I envision leading our team to phenomenal success by continuously pushing the boundaries of multi-omic innovation and translating that science into real-world impact.

Our mission is bold: to decode biology at an unprecedented level of resolution and transform how researchers and clinicians understand disease. I believe in empowering a world-class team of scientists, engineers, and visionaries who thrive at the intersection of disciplines, while fostering a culture that rewards creativity, urgency, and scientific rigor.

By building strategic partnerships, delivering powerful tools that simplify complex biology, and remaining focused on the needs of translational medicine, we aim not only to shape the future of diagnostics and therapeutics but also to define a new standard for what is possible in biotechnology.

My goal is to leave a lasting legacy rooted in innovation, integrity, and meaningful impact.

Company Name: Codetta Bio
CEO: Jacques Corriveau
Website: www.codettabio.com